143 related articles for article (PubMed ID: 8067752)
1. Effective monitoring of concentrations of ofloxacin in saliva of patients with chronic respiratory tract infections.
Koizumi F; Ohnishi A; Takemura H; Okubo S; Kagami T; Tanaka T
Antimicrob Agents Chemother; 1994 May; 38(5):1140-3. PubMed ID: 8067752
[TBL] [Abstract][Full Text] [Related]
2. Secretion of ofloxacin into saliva in patients with respiratory tract infection.
Takagi K; Hasegawa T; Yamaki K; Suzuki K; Nabeshima T
Int J Clin Pharmacol Ther Toxicol; 1992 Feb; 30(2):46-50. PubMed ID: 1551745
[TBL] [Abstract][Full Text] [Related]
3. Respiratory tract penetration of quinolone antimicrobials: a case in study.
Ritrovato CA; Deeter RG
Pharmacotherapy; 1991; 11(1):38-49. PubMed ID: 2020610
[TBL] [Abstract][Full Text] [Related]
4. [Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint].
Fujita A; Miya T; Tanaka R; Hirayama S; Isaka H; Ono Y; Koshiishi Y; Goya T
Jpn J Antibiot; 1999 Nov; 52(11):661-6. PubMed ID: 10659442
[TBL] [Abstract][Full Text] [Related]
5. [Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections].
Nakamori Y; Tsuboi E; Narui K; Nakatani T; Nakata K; Sugi H
Jpn J Antibiot; 1992 May; 45(5):539-47. PubMed ID: 1512940
[TBL] [Abstract][Full Text] [Related]
6. Ofloxacin concentrations in tissues involved in respiratory tract infections.
Perea EJ
J Antimicrob Chemother; 1990 Nov; 26 Suppl D():55-60. PubMed ID: 2286591
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of ofloxacin--measurement of drug concentration in saliva of patients with impaired renal function.
Fujita K; Matsuoka N; Takenaka I; Hiraishi K; Yokota T; Asahi T; Tatara K; Yuasa M; Kaifu Y; Kawano A
Drugs; 1995; 49 Suppl 2():312-3. PubMed ID: 8549345
[No Abstract] [Full Text] [Related]
8. Multiple-dose pharmacokinetics of ofloxacin in serum, saliva, and skin blister fluid of healthy volunteers.
Warlich R; Korting HC; Schäfer-Korting M; Mutschler E
Antimicrob Agents Chemother; 1990 Jan; 34(1):78-81. PubMed ID: 2327762
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections.
Nakamori Y; Miyashita Y; Nakatani I; Nakata K
Drugs; 1995; 49 Suppl 2():418-9. PubMed ID: 8549384
[No Abstract] [Full Text] [Related]
10. Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.
Kovarik JM; Hoepelman AI; Smit JM; Sips PA; Rozenberg-Arska M; Glerum JH; Verhoef J
Antimicrob Agents Chemother; 1992 Nov; 36(11):2458-61. PubMed ID: 1336948
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetic study of ofloxacin using saliva concentration in chronic renal failure].
Tsubakihara Y; Hayashi T; Shoji T; Kitamura E; Okada N; Nakanishi I
Nihon Jinzo Gakkai Shi; 1994 Mar; 36(3):246-9. PubMed ID: 8196221
[TBL] [Abstract][Full Text] [Related]
12. The penetration of ofloxacin into bronchial secretions.
Symonds J; Javaid A; Bone M; Turner A
J Antimicrob Chemother; 1988 Sep; 22 Suppl C():91-5. PubMed ID: 3182469
[TBL] [Abstract][Full Text] [Related]
13. [Serum and sputum levels of cefotetan used in respiratory tract infections].
Matsumoto Y; Hitsuda Y; Sugimoto Y; Ishikawa J; Sasaki T
Jpn J Antibiot; 1986 Oct; 39(10):2690-4. PubMed ID: 3468274
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of ofloxacin on acute exacerbations of chronic respiratory tract infections in comparison with erythromycin.
Kawahara S; Watanabe Y; Matsuka Y; Sato T; Takahashi K
Drugs; 1995; 49 Suppl 2():414-5. PubMed ID: 8549382
[No Abstract] [Full Text] [Related]
15. Ofloxacin concentrations in serum, saliva and pleural effusion of patients with pulmonary tuberculosis and lung cancer.
Miya T; Hamakubo S; Goya T; Hanaoka T; Hosaka K
Jpn J Antibiot; 1995 Jul; 48(7):960-4. PubMed ID: 7563589
[TBL] [Abstract][Full Text] [Related]
16. [Laboratory and clinical studies on levofloxacin].
Tanaka K; Iwamoto M; Maesaki S; Koga H; Kohno S; Hara K; Sugawara K; Kaku M; Kusano S; Sakito O
Jpn J Antibiot; 1992 May; 45(5):548-56. PubMed ID: 1512941
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics and clinical efficacy of ciprofloxacin in aged patients with chronic respiratory diseases].
Teramoto S; Fukuchi Y; Nagase T; Orimo H
Jpn J Antibiot; 1992 May; 45(5):507-11. PubMed ID: 1512936
[TBL] [Abstract][Full Text] [Related]
18. Role of chronic Pseudomonas aeruginosa infection in airway mucosal permeability.
Ishihara H; Honda I; Shimura S; Sasaki H; Takishima T
Chest; 1991 Dec; 100(6):1607-13. PubMed ID: 1959404
[TBL] [Abstract][Full Text] [Related]
19. Serum, saliva, and sputum levels of metronidazole in acute exacerbations of chronic bronchitis.
Siegler D; Kaye CM; Reilly S; Willis AT; Sankey MG
Thorax; 1981 Oct; 36(10):781-3. PubMed ID: 7330795
[TBL] [Abstract][Full Text] [Related]
20. Trimethoprim alone compared to co-trimoxazole in lower respiratory infections: pharmacokinetics and clinical effectiveness.
Brumfitt W; Hamilton-Miller JM; Havard CW; Tansley H
Scand J Infect Dis; 1985; 17(1):99-105. PubMed ID: 3873108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
